Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

STATEN ISLAND, N.Y., Nov. 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections announced the publication of results from its scientific collaboration with Leiden University Medical Center (LUMC) demonstrating structural biology research that reveals for the first time a DNA pol IIIC inhibitor, ibezapolstat, bound to its target. The publication is entitled: A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens. The senior author is Wiep Klaas Smits, PhD, Associate Professor and Principal Investigator for Pol C Inhibitors, Leiden University Medical Center, Netherlands.

Read more at prnewswire.com